Search - tctmd.com

Displaying 1 - 20 of 39

Sort: Relevancy | Date

News Daily News

PCSK9 Variants Linked With Lower LDL Cholesterol, Increased Diabetes Risk

Michael O'Riordan

December 01, 2016

News Daily News

FH Screening Started at Time of Childhood Immunization Feasible and Effective

Michael O'Riordan

October 28, 2016

News Industry News

Amgen Announces Positive Top-Line Results From Phase 3 GLAGOV Imaging Study Of Repatha® (Evolocumab)

September 20, 2016

News Daily News

更高效、更廉价：成本效益分析称 PCSK9 价格需降低三分之二

Yael L. Maxwell

August 29, 2016

News Daily News

More Bang, Less Buck: Cost-Effectiveness Analysis Says Price of PCSK9 Inhibitors Needs to Drop by Two-Thirds

Yael L. Maxwell

August 29, 2016

News Daily News

Más con Menos: Un Análisis de Rentabilidad Dice que Hay que Reducir en Dos Tercios el Precio de PCSK9

Yael L. Maxwell

August 29, 2016

News Conference News ESC 2016

Focus on LDL Cholesterol Targets With Statin Therapy, New ESC-EAS Cholesterol Guidelines Say

Michael O'Riordan

August 27, 2016

News Opinion Editor's Corner

ESC 2016: Bare-Metal Flashbacks, Coronary Imaging Comparisons, Heart Team Hype, and His Holiness

Shelley Wood

August 24, 2016

News Daily News

USPSTF: Not Enough Evidence to Recommend Routine Lipid Screening in Children and Adolescents

Michael O'Riordan

August 09, 2016

News Daily News

Judge Dismisses AstraZeneca’s Bid to Block Generic Crestor

Shelley Wood

July 20, 2016

News Daily News

AstraZeneca Strives to Block Generic Crestor as Observers Call Foul

Michael O'Riordan

July 13, 2016

News Daily News

他汀类药物可降低家族性高胆固醇患者的冠心病和死亡的额外风险，但不能完全消除

Todd Neale

July 12, 2016

News Daily News

Statins Lower but Don’t Erase the Excess Risk of Coronary Disease and Death in Familial Hypercholesterolemia

Todd Neale

July 12, 2016

News Daily News

Las Estatinas Minimizan pero No Eliminan el Exceso de Riesgo de Enfermedad Coronaria y Muerte en la Hipercolesterolemia Familiar

Todd Neale

July 12, 2016

News Industry News

FDA Approves First And Only Single Monthly Injection For A PCSK9 Inhibitor

July 11, 2016

News Daily News

Adverse Events Linked with Statins Get a Second Look From Cholesterol Treatment Trialists’ Collaboration

Michael O'Riordan

June 13, 2016

News Daily News

Detection and Treatment of Severe FH Depends on LDL Levels, Not Genes, Says Expert Panel

Michael O'Riordan

June 09, 2016

News Conference News ACC 2016

Statin Intolerance and FH: GAUSS-3 Finds Benefit With Evolocumab, While Another Study Exposes Lifetime Risks of FH

Michael O'Riordan

April 03, 2016

News Opinion Editor's Corner

ACC 2016: HOPE for Primary Prevention, TAVR in Moderate-Risk Patients, Deferred Stenting in STEMI, and More

Shelley Wood

March 28, 2016

News Features

PCSK9 Inhibitors: Good Early Responses With Pricey Drugs, but Doctors Still Waiting on Real Data

Michael O'Riordan

January 25, 2016

Advertisement

PCSK9 Variants Linked With Lower LDL Cholesterol, Increased Diabetes Risk

FH Screening Started at Time of Childhood Immunization Feasible and Effective

Amgen Announces Positive Top-Line Results From Phase 3 GLAGOV Imaging Study Of Repatha® (Evolocumab)

更高效、更廉价：成本效益分析称 PCSK9 价格需降低三分之二

More Bang, Less Buck: Cost-Effectiveness Analysis Says Price of PCSK9 Inhibitors Needs to Drop by Two-Thirds

Más con Menos: Un Análisis de Rentabilidad Dice que Hay que Reducir en Dos Tercios el Precio de PCSK9

Focus on LDL Cholesterol Targets With Statin Therapy, New ESC-EAS Cholesterol Guidelines Say

ESC 2016: Bare-Metal Flashbacks, Coronary Imaging Comparisons, Heart Team Hype, and His Holiness

USPSTF: Not Enough Evidence to Recommend Routine Lipid Screening in Children and Adolescents

Judge Dismisses AstraZeneca’s Bid to Block Generic Crestor

AstraZeneca Strives to Block Generic Crestor as Observers Call Foul

他汀类药物可降低家族性高胆固醇患者的冠心病和死亡的额外风险，但不能完全消除

Statins Lower but Don’t Erase the Excess Risk of Coronary Disease and Death in Familial Hypercholesterolemia

Las Estatinas Minimizan pero No Eliminan el Exceso de Riesgo de Enfermedad Coronaria y Muerte en la Hipercolesterolemia Familiar

FDA Approves First And Only Single Monthly Injection For A PCSK9 Inhibitor

Adverse Events Linked with Statins Get a Second Look From Cholesterol Treatment Trialists’ Collaboration

Detection and Treatment of Severe FH Depends on LDL Levels, Not Genes, Says Expert Panel

Statin Intolerance and FH: GAUSS-3 Finds Benefit With Evolocumab, While Another Study Exposes Lifetime Risks of FH

ACC 2016: HOPE for Primary Prevention, TAVR in Moderate-Risk Patients, Deferred Stenting in STEMI, and More

PCSK9 Inhibitors: Good Early Responses With Pricey Drugs, but Doctors Still Waiting on Real Data

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content